<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="745">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05151458</url>
  </required_header>
  <id_info>
    <org_study_id>NGAL in IBD</org_study_id>
    <nct_id>NCT05151458</nct_id>
  </id_info>
  <brief_title>Serum NGAL as a Predictor of Clinical and Endoscopic Activity of Inflammatory Bowel Disease</brief_title>
  <official_title>Serum NGAL as a Predictor of Clinical and Endoscopic Activity of Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ulcerative colitis (UC) and Crohns disease (CD) represent the two major forms of inflammatory&#xD;
      bowel disease (IBD), characterized by epithelial cell damage and prominent mucosal&#xD;
      infiltration by inflammatory cells including granulocytes, macrophages, lymphocytes, and&#xD;
      plasma cells.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 29, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 29, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>test the sensitivity and specificity of using NGAL in diagnosis of IBD</measure>
    <time_frame>One year</time_frame>
    <description>test the sensitivity and specificity of using NGAL in diagnosis of IBD</description>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with IBD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: IBD patients diagnosed by endoscopy.&#xD;
&#xD;
        Male and female gender. Disease activity proven clinically and endoscopy . Assiut&#xD;
        university hospital patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refuse to contribute in this study Pregnancy and breast feeding Cancer&#xD;
             patients Renal pathology Diabetes Mellitus Cardiovascular patients Pancreatitis COPD&#xD;
             patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mohamed Alsadek Ma Ghozaly, Master</last_name>
    <phone>01150993206</phone>
    <email>alsadekmohamed215@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hossam Ma Abd Alwahab</last_name>
    <phone>01146539976</phone>
  </overall_contact_backup>
  <reference>
    <citation>Oikonomou KA, Kapsoritakis AN, Theodoridou C, Karangelis D, Germenis A, Stefanidis I, Potamianos SP. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J Gastroenterol. 2012 May;47(5):519-30. doi: 10.1007/s00535-011-0516-5. Epub 2011 Dec 27.</citation>
    <PMID>22200942</PMID>
  </reference>
  <reference>
    <citation>Nakov R. New markers in ulcerative colitis. Clin Chim Acta. 2019 Oct;497:141-146. doi: 10.1016/j.cca.2019.07.033. Epub 2019 Jul 27. Review.</citation>
    <PMID>31361991</PMID>
  </reference>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>December 12, 2021</last_update_submitted>
  <last_update_submitted_qc>December 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohamed Alsadek Mahmoud Ghozaly</investigator_full_name>
    <investigator_title>Serum NGAL as a predictor of clinical and endoscopic activity of inflammatory bowel disease</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

